PMID- 30974886
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 4
DP  - 2019 Apr 10
TI  - Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design.
LID - 10.3390/jcm8040486 [doi]
LID - 486
AB  - Accurate antiviral humoral and cellular immune responses require prior 
      recognition of antigenic peptides presented by human leukocyte antigen (HLA) 
      class I and II molecules on the surface of antigen-presenting cells. Both the 
      helper and the cytotoxic immune responses are critical for the control and the 
      clearance of human respiratory syncytial virus (HRSV) infection, which is a 
      significant cause of morbidity and mortality in infected pediatric, 
      immunocompromised and elderly populations. In this article we review the 
      immunoproteomics studies which have defined the general antigen processing and 
      presentation rules that determine both the immunoprevalence and the 
      immunodominance of the cellular immune response to HRSV. Mass spectrometry and 
      functional analyses have shown that the HLA class I and II cellular immune 
      responses against HRSV are mainly focused on three viral proteins: fusion, 
      matrix, and nucleoprotein. Thus, these studies have important implications for 
      vaccine development against this virus, since a vaccine construct including these 
      three relevant HRSV proteins could efficiently stimulate the major components of 
      the adaptive immune system: humoral, helper, and cytotoxic effector immune 
      responses.
FAU - Lopez, Daniel
AU  - Lopez D
AD  - Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 
      Majadahonda (Madrid), Spain. dlopez@isciii.es.
FAU - Barriga, Alejandro
AU  - Barriga A
AD  - Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 
      Majadahonda (Madrid), Spain. abarriga@isciii.es.
FAU - Lorente, Elena
AU  - Lorente E
AD  - Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 
      Majadahonda (Madrid), Spain. elorente@isciii.es.
FAU - Mir, Carmen
AU  - Mir C
AD  - Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 
      Majadahonda (Madrid), Spain. c.mir@isciii.es.
LA  - eng
GR  - BIO2011-25636/Spanish Ministry of Economy/
GR  - SAF2014-58052/Spanish Ministry of Economy/
GR  - Accion Estrategica en Salud 2018/Spanish Ministry of Economy/
PT  - Journal Article
PT  - Review
DEP - 20190410
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6518116
OTO - NOTNLM
OT  - Antigen processing
OT  - HLA
OT  - T cells
OT  - immune response
OT  - immunoproteomics
OT  - mass spectrometry
OT  - respiratory infectious disease
OT  - vaccine
COIS- The authors declare no conflict of interest.
EDAT- 2019/04/13 06:00
MHDA- 2019/04/13 06:01
PMCR- 2019/04/10
CRDT- 2019/04/13 06:00
PHST- 2019/03/08 00:00 [received]
PHST- 2019/04/01 00:00 [revised]
PHST- 2019/04/09 00:00 [accepted]
PHST- 2019/04/13 06:00 [entrez]
PHST- 2019/04/13 06:00 [pubmed]
PHST- 2019/04/13 06:01 [medline]
PHST- 2019/04/10 00:00 [pmc-release]
AID - jcm8040486 [pii]
AID - jcm-08-00486 [pii]
AID - 10.3390/jcm8040486 [doi]
PST - epublish
SO  - J Clin Med. 2019 Apr 10;8(4):486. doi: 10.3390/jcm8040486.